Smilax Laboratories Profile
Key Indicators
- Authorised Capital ₹ 97.00 Cr
- Paid Up Capital ₹ 96.04 Cr
- Company Age 20 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 11.51 Cr
- Satisfied Charges ₹ 465.93 Cr
- Revenue Growth 33.66%
- Profit Growth 129.33%
- Ebitda 216.49%
- Net Worth 3.35%
- Total Assets -3.56%
About Smilax Laboratories
Smilax Laboratories Limited (SLL) is a leading Public Limited Indian Non-Government Company incorporated in India on 20 October 2004 and has a history of 20 years and four months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 97.00 Cr and a paid-up capital of Rs 96.04 Cr.
The company currently has active open charges totaling ₹11.51 Cr. The company has closed loans amounting to ₹465.93 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Smilax Laboratories Limited India are Shrishti Palod as COMPANY SECRETARY and Pulicherla Ganesh as Cfo. Ramakrishna Munnamgi, Saibaba Eadala, Surender Geedipalli, and One other member serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U24230TG2004PLC044461
- Company No.
044461
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
20 Oct 2004
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Smilax Laboratories Limited offer?
Smilax Laboratories Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, API Intermediate, Cardiovascular Drugs & Medication, Anticoagulant and Antiplatelet Drugs, Brain & Nervous System Drugs, Psychotherapeutic Agents, Anti Infective Drugs & Medicines, HIV Drugs, Blood Pressure Medicine, Antimigraine Drug.
Who are the key members and board of directors at Smilax Laboratories?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Shrishti Palod | Company Secretary | 30-Dec-2023 | Current |
| Pulicherla Ganesh | CFO | 15-Nov-2021 | Current |
Suryadevara Krishna  | Managing Director | 01-Mar-2010 | Current |
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ramakrishna Munnamgi | Director | 25-Jun-2019 | Current |
| Saibaba Eadala | Director | 24-Sep-2021 | Current |
| Surender Geedipalli | Director | 24-Sep-2021 | Current |
Financial Performance of Smilax Laboratories.
Smilax Laboratories Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 33.66% increase. The company also saw a substantial improvement in profitability, with a 129.33% increase in profit. The company's net worth moved up by a moderate rise of 3.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Smilax Laboratories?
In 2023, Smilax Laboratories had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Voyants Solutions Private LimitedSurender Geedipalli is a mutual person
Kvr Baseline Resources Private LimitedRamakrishna Munnamgi is a mutual person
Ramky Life Sciences LimitedRamakrishna Munnamgi is a mutual person
- Ramky Viha Properties Private Limited
Saibaba Eadala and Surender Geedipalli are mutual person
- Ramky Srisairam Properties Private Limited
Saibaba Eadala and Surender Geedipalli are mutual person
- Ramky Integrated Township Limited
Saibaba Eadala and Surender Geedipalli are mutual person
Charges (Loans)
₹11.51 Cr
₹465.93 Cr
Charges Breakdown by Lending Institutions
- Bank Of India : 11.51 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 29 Nov 2006 | Bank Of India | ₹11.51 Cr | Open |
| 28 Mar 2016 | Axis Bank Limited | ₹85.00 Cr | Satisfied |
| 31 Mar 2014 | Idfc Limited | ₹100.00 Cr | Satisfied |
| 24 Mar 2014 | Idfc Limited | ₹37.50 Cr | Satisfied |
| 29 May 2009 | Andhra Bank | ₹81.89 Cr | Satisfied |
How Many Employees Work at Smilax Laboratories?
Smilax Laboratories has a workforce of 521 employees as of Apr 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Smilax Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Smilax Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
